Latest Share Chat

Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 45.75

Bid: 45.50

Ask: 46.00

Change: 1.00 (2.19%)

Spread: 0.50 (1.099%)

Open: 45.00

High: 46.75

Low: 44.25

Prev. Close: 45.75

Last checked at -

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Thu, 01st Oct 2020 06:40

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Launches bead-assisted mass spectrometry, or BAMS, SARS-CoV-2 virus test. "The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals," Avacta says. Adds that one thousand samples per day can be analysed by a single technician using BAMS.

Current stock price: 155.00 pence, up 11% on Wednesday.

Year-to-date change: up sharply from 17.25p

By Eric Cunha; ericcunha@alliancenews.com

More News

16 Mar 2022 11:38

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

3 Feb 2022 12:31

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.

3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

18 Jan 2022 13:52

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Avacta sells veterinary division to Vimian for up to GBP2.3 million

Avacta moves to next dose in first-in-human chemotherapy trial

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta Group selects second pro-drug candidate

Avacta selects potential tumour treatment for preclinical development

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Abingdon Health plunges after Avacta stops selling Covid-19 test

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Shares plummet as Avacta pauses sale of lateral flow tests

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Avacta shares up as flow tests receive CE mark for self-test use

Avacta confirms lateral flow tests can detect Omicron variant

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Login to your account

Quickpicks are a member only feature

Login to your account